Cancer Biomarkers Market

Cancer Biomarkers Market

Cancer Biomarkers Market (2nd Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Biomarker (HER2, MET, EGFR, PD-L1, NTRK, ALK, Novel Biomarkers and Other Biomarkers), Type of Cancer (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia) and Key Geographical Regions (North America, Europe and Asia-Pacific)

The cancer biomarkers market is valued at USD 28.6 billion in 2024 growing at a CAGR of 5% during the forecast period 2024-2035.

The healthcare industry has witnessed a significant evolution in cancer treatment options over the past few decades, with the introduction of various targeted therapies, immunotherapies, and anti-cancer vaccines. However, clinical cancer research continues to face substantial challenges, including high failure rates, drug / therapy limitations, and potentially fatal adverse effects. A prominent concern revolves around determining the appropriate treatment option for a specific type of cancer, as patients with the same cancer stage and type may exhibit different molecular profiles, leading to varying responses to recommended treatments. To address this concern, pharmaceutical developers and healthcare professionals have adopted a personalized approach known as oncology precision medicine. This approach involves identifying and characterizing molecular markers, many of which have been validated for use in making crucial treatment decisions.

While single analyte biomarkers, such as PD-L1, BRAF, and EGFR, have played an established role across multiple cancer indications, their sole use has proven insufficient in determining patient responses due to subtle differences in individual genomic makeups. Advances in biotechnology have facilitated the development of high-throughput tools, enabling the establishment of better biomarkers based on genome/exome profiles. Novel biomarkers, including tumor mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumor-infiltrating lymphocytes (TILs), Single Nucleotide Variants (SNVs), Copy Number Variants (CNVs), and others, are currently being investigated across numerous clinical studies.

Several diagnostics companies have developed or are developing analytical tests for these biomarkers, aimed at assisting physicians in making personalized treatment decisions. Notably, many major pharmaceutical players have shown interest in this domain and have launched clinical research initiatives to investigate the relevance and applications of multiple novel biomarkers.

With the growing interest from established companies and startups alike, the cancer biomarker market is poised for robust growth at a healthy compound annual growth rate (CAGR) in the forecast period, driven by the need for personalized and precise cancer treatment strategies.

Key Market Segments

Type of Biomarker

HER2

MET

EGFR

PD-L1

NTRK

ALK

Novel Biomarkers

Other Biomarkers

Type of Cancer

Breast Cancer

Prostate Cancer

Colorectum Cancer

Lung Cancer

Thyroid Cancer

Bladder Cancer

Melanoma

Non-Hodgkins Lymphoma

Endometrial Cancer

Kidney Cancer

Leukemia

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

The report studies the cancer biomarkers market based on type of biomarker, type of cancer, and key geographical regions

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to four major regions

This comprehensive report provides an in-depth analysis of cancer biomarkers and the associated market landscape. It begins with a general overview of cancer biomarkers, highlighting their importance in the healthcare industry and detailing the different types of biomarkers and their identification methods. The report also delves into novel biomarkers, their variations, and measurement techniques.

The report then offers a detailed assessment of the overall market landscape for testing solutions for novel cancer biomarkers. It covers various relevant parameters, such as biomarker types (MSI/MMR, TMB, TILs, SNV, and CNV), profiling technologies (genomics, immunoassay, bioinformatics, cytogenetics, and others), analytical techniques (next-generation sequencing, PCR, immunohistochemistry, whole-exome sequencing, and others), turnaround time, sample inputs (FFPE tissue, blood, plasma, and other bodily fluids), nucleic acid types (DNA and RNA), cancer types (bladder, breast, CNS, colorectal, endometrial, gastrointestinal, hematologic, lung, melanoma, ovarian, prostate, and others), and application areas (research and development, diagnostics, prognostics, disease risk assessment, and others). Additionally, the report provides a detailed list of developers offering novel cancer biomarker testing solutions, along with an analysis based on factors such as year of establishment, company size, and headquarters location.

The report includes a product competitiveness analysis of novel cancer biomarker testing solutions, based on product versatility (number of biomarkers evaluated and cancers targeted) and competitiveness (number of profiling technologies, analytical techniques, sample inputs, and turnaround time). It also features elaborate profiles of prominent players in the cancer biomarkers market, including overviews, financial information, product portfolios, recent developments, and future outlooks.

Furthermore, the report explores innovative study designs involved in conducting biomarker-based clinical trials for oncological disorders, highlighting the structure, advantages, and challenges of each design. It also provides a comprehensive clinical trial analysis of completed, ongoing, and planned studies focused on assessing novel cancer biomarkers (TMB, MSI/MMR, SNV, CNV, and TILs), based on parameters such as trial year, status, phase, patient population, sponsor type, active players, study design, therapeutic area, and geographical regions.

The report includes a detailed publication analysis of over 630 articles published between 2019 and 2023, highlighting the key focus areas of ongoing research related to novel cancer biomarkers. It covers trends based on publication year, type, cancer type, copyright holders, emerging focus areas, active publishers, and key journals.

Additionally, the report features a benchmark analysis of various big pharma players engaged in the cancer biomarkers domain, comparing their initiatives based on multiple relevant parameters and providing a heat map representation of their distribution across various parameters.

The report also discusses the various steps involved in the production of companion diagnostics, including R&D, clinical assessment, manufacturing and assembly, payer negotiation, marketing activities, and cost distribution across these stages.

Furthermore, the report explores upcoming opportunities for cancer biomarker testing solution providers, such as the rise in biomarker-based oncology clinical trials, increasing focus on precision medicine, and the development of companion diagnostic products.

The report provides a detailed cancer biomarkers market forecast analysis, including estimates of the existing market size, market value, and future opportunity for cancer biomarker companies over the next 12 years (2024-2035). It offers detailed projections of the current and future market opportunity across different types of biomarkers (HER2, MET, EGFR, PD-L1, NTRK, ALK, novel biomarkers, and others), cancer types (breast, prostate, colorectal, lung, thyroid, bladder, melanoma, non-Hodgkin lymphoma, endometrial, kidney, and leukemia), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the cancer biomarkers market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

Agilent

ARUP Laboratories

BioReference

Foundation Medicine

OncoDNA

Q² Solutions

Thermo Fisher Scientific

YuceBio

Asper Biogene

Caris Life Sciences

CeGaT

Genekor Medical

Guardant Health

Labcorp

MedGenome

NeoGenomics Laboratories

Nonacus

Oxford Gene Technology

Personal Genome Diagnostics

PhenoPath

Positive Biosciences

Quest Diagnostics

Tempus